Yung Shin Pharmaceutical

Company snapshot

1952年，創辦人李天德先生於故鄉大甲創立了永信西藥房，一個以「提供最佳藥品、增進人們健康」為使命的品牌於焉誕生。從白色的製藥廠房、銷售人員的白襯衫和白色偉士牌機車，六十年來，永信始終以白色所代表的純潔正直、無瑕的品質，作為守護人們健康的傳統精神。 數十年來，永信集團持續以服務、誠信、創新之精神，秉持著「藥，是做給家人吃的」的品質精神，實踐「謢衛健康、創造美麗與傳遞快樂」的公司願景。 永信對於財務透明、純正無瑕的品質堅持，從六十年前以單一帳冊管理財務的經營策略，到近年來引進德國SAP標準化的ERP系統作為資訊系統的控管，致力於讓成本透明化、管理制度化、品質標準化，以提供社會大眾安心、安全的藥品與全方位的健康解決方案。 永信相信製藥業者必須要嚴謹，追求完美且表裡如一，如果沒有正直的心，就無法製造讓人安心的藥品，如果不能讓人們安心，就無法贏得消費者的信任。 竭誠歡迎認同永信經營理念的您，加入永

• 10 active pipeline program(s) linked via ClinicalTrials.gov.
• 10 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Yung Shin Pharmaceutical. Not investment advice.

• Peer + 0 momentum

  Boehringer Ingelheim

  TA overlap score 40

• Peer + 0 momentum

  Rhythm Pharmaceuticals Netherlands

  TA overlap score 34.6

• Peer + 0 momentum

  Quantum Pharmaceuticals

  TA overlap score 23.6

Recent activity

Latest pipeline, patent, and corporate events for Yung Shin Pharmaceutical.

1. Jun 8, 2026 Clinical update

   Rabeprazole Sodium 10mg — Phase 1

2. Jun 8, 2026 Clinical update

   Prednisone + Jakavi(ruxolitinib) — Phase 2

3. Jun 8, 2026 Clinical update

   Fimasartan/Atorvastatin Combination Tablet — Phase 1

4. Jun 8, 2026 Clinical update

   Fimasartan and Rosuvastatin — Phase 3

5. May 26, 2026 Clinical update

   dabigatran — Phase 3

View all clinical trial activity →

• What is Yung Shin Pharmaceutical?

  Yung NA is a pharma organization headquartered in CN. Primary therapeutic focus areas include Hypertension, Gastric Ulcer, Atrial Fibrillation, Essential Hypertension, Dyslipidemia, Essential Hypertension. NovaPharmaNews links 10 clinical program(s), 0 drug profile(s), and 0 pate

• Is Yung Shin Pharmaceutical publicly traded?

  Yung Shin Pharmaceutical appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Yung Shin Pharmaceutical develop or market?

  We link 13 drug profile(s) where Yung Shin Pharmaceutical is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/yung-na#company-drugs.

• What are the latest developments for Yung Shin Pharmaceutical?

  In the last 12 months our linked public records show 10 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Yung Shin Pharmaceutical focus on?

  Yung Shin Pharmaceutical focuses on Hypertension, Gastric Ulcer, Atrial Fibrillation based on our analysis of their pipeline programs and drug development activities.